Buying MDMA pills Karlsruhe

__________________________

📍 Verified store!

📍 Guarantees! Quality! Reviews!

__________________________

▼▼ ▼▼ ▼▼ ▼▼ ▼▼ ▼▼ ▼▼

▲▲ ▲▲ ▲▲ ▲▲ ▲▲ ▲▲ ▲▲

Buying MDMA pills Karlsruhe

Veterinarian Karlsruhe - veterinary medicine cabinet. Veterinarians have the authority to sell medicines and thus operate a veterinary medicine cabinet. Unlike human physicians who must prescribe medications that must then be purchased at a regular pharmacy, veterinarians are authorized to sell medications directly to their patients. However, this permit only applies to the animals he treats and is subject to strict regulations, particularly when it comes to the sale of antibiotics. It is essential to understand that medications cannot be easily sold. Sales or prescription may only take place as part of a treatment. No exceptions are allowed, even if there is a prescription for the medication. In addition, prescriptions for animals may only be filled in conventional pharmacies. The use of antibiotics in animals has become increasingly regulated in recent years. This particularly impacts pet owners who have access to these medications through their veterinarians. A key rule is that antibiotics may only be used after the animal has been examined by a veterinarian. There are also certain antibiotics that are completely prohibited from being used in dogs and cats. In addition, extensive laboratory tests must be carried out when using some antibiotics. This is intended to ensure that the drug is suitable for the specific case and help minimize the risk of resistance developing. A crucial aspect for the veterinary medicine cabinet is the return and disposal of medication. Once a medication has been dispensed, the vet may not take it back or refund it. This is to ensure the safety and effectiveness of the medication. Extreme caution should be exercised when disposing of medications. It is strictly forbidden to pour any medications, including liquid medications, down the sink or toilet. However, if your community's household waste is sent for incineration, it is acceptable to put medicines in the household waste. It is always advisable to follow local regulations regarding the disposal of medication. It is the veterinarian's responsibility to ensure the health and well-being of the animals entrusted to their care. This includes the correct prescription and use of medications, proper storage and disposal, and compliance with applicable regulations and guidelines. The responsible use of medication not only contributes to the health of the individual animal, but also to the well-being of the entire animal population. It is essential that veterinarians stay up to date with current regulations and best practices to ensure the best possible care for their animal patients. This ensures that both veterinarians and pet owners do the best for their animals and contribute to a sustainable and healthy wildlife. In the dynamic world of veterinary medicine, it is essential for veterinarians to keep their knowledge and skills up to date. Regular training and access to current research are key elements in ensuring that treatment strategies meet the most current standards. These efforts to continually improve and update are critical to the well-being of animal patients and the satisfaction of pet owners. Adhering to regulations and ethical standards is of utmost importance for every veterinarian. Compliance with these regulations not only ensures the legal operation of the veterinary medicine cabinet, but also helps maintain trust between the veterinarian and the animal owner. Respectful and ethical treatment of animals is a basic requirement for practicing the profession of veterinarian and serves to protect and promote the welfare of animals. According to the Medicines Act AMG , veterinarians in Germany are allowed to sell medications that are used in the treatment of their animal patients. This includes a wide range of medications including, but not limited to, antibiotics, pain relievers, and medications used to treat chronic conditions. The regulations for the use of antibiotics in veterinary medicine have been tightened in recent years in order to prevent the development of antibiotic resistance. According to the Regulation on the Use of Veterinary Medicines TAMV , your animal must be examined by a veterinarian before antibiotics are prescribed to ensure that the use of antibiotics is justified and safe. Veterinarians are not allowed to take back any medication except for destruction. If you have unused or expired medications, they should be disposed of correctly. In most communities, medications can be disposed of with household waste if it is incinerated. Please never pour medications, including liquid medications, down the sink or toilet. Veterinarians are bound by the Animal Protection Act TierSchG and the professional regulations of the respective state veterinary association, which establish clear ethical guidelines and responsibilities. In addition, the Medicines Act AMG requires veterinarians to comply with certain standards when selling and prescribing medications. If you have any concerns, please speak to your veterinarian or contact your local veterinary association. The veterinary medicine cabinet requires a high level of responsibility, expertise and ethics. From properly selling and prescribing medications, to properly disposing of medications, to complying with the latest regulations and providing quality veterinary care, veterinarians always strive to do the best for their patients and their owners. By carefully handling these tasks, veterinarians make a valuable contribution to promoting the health and well-being of the animals in their care. In Germany, the Medicines Act AMG forms the basis for the regulations surrounding the dispensing and sale of medication in the veterinary medicine cabinet. Since , new regulations on the use of antibiotics in veterinary medicine have been in effect in Germany. Particularly noteworthy here are the regulations on antibiotic resistance monitoring and the prescribed measures to prevent resistance. Veterinarians must adhere to these regulations to ensure environmentally sound and safe disposal of unused or expired medications. With regard to ethical questions and responsibility in veterinary medicine, the Animal Protection Act TierSchG and the professional regulations of the respective state veterinary association are particularly relevant. These establish, among other things, the welfare of the animal as the primary goal of veterinary work and define the ethical duties of the veterinarian. The book addresses the increasingly important issue of the environmental impact of veterinary drugs. It deals with the consequences of improper disposal of medication and offers suggestions for responsible action. An essential handbook for all veterinarians, providing a detailed overview of the most important aspects of veterinary pharmacology. It covers, among other things, the correct prescribing and administration of medication. Gerber and Markus Hilty. This book offers a deep insight into the complex topic of antibiotic resistance. It analyzes the problem from both the perspective of human medicine and veterinary medicine and discusses solutions. A comprehensive work that deals with the ethical aspects of veterinary medicine, including the responsibility of veterinarians in the use of medication and the obligation to comply with animal welfare standards. A useful reference work for all legal questions in veterinary practice. If you have any questions, please feel free to contact one of our veterinarians. Veterinary medicine cabinet: regulations and guidelines Contents. Veterinary medicine cabinet: regulations and guidelines Prescribing and selling medications in the veterinary practice Veterinary medicine cabinet: Special regulations for handling antibiotics Veterinary medicine cabinet: return and disposal of medications Animal health and responsibility of the veterinarian - veterinary medicine cabinet Further training and current information for veterinarians on the subject of veterinary medicine cabinets Compliance with regulations and ethical standards Frequently asked questions FAQs about veterinary medicine cabinets: Which medications can my veterinarian sell directly in the practice? Why does my pet need to be examined before antibiotics can be prescribed? What happens if I have leftover medication? How can I be sure my veterinarian is following ethical standards? Summary Legal basis for the sale of medication in veterinary practices through the veterinary medicine cabinet Special regulations for antibiotics for the veterinary medicine cabinet Regulations for the disposal of medication Veterinary medicine cabinet: Ethics in veterinary medicine Further literature references on veterinary medicine cabinets. Which medications can my veterinarian sell directly in the practice? No similar items found. We use cookies to optimize our website and our service. Functional Functional Always active Technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service expressly requested by the subscriber or user or for the sole purpose of carrying out the transmission of a message over an electronic communications network. Technical storage or access is necessary for the legitimate purpose of storing preferences not requested by the Subscriber or User. Technical storage or access carried out exclusively for statistical purposes. Technical storage or access used exclusively for anonymous statistical purposes. Without a subpoena, the voluntary consent of your Internet service provider, or additional records from third parties, the information stored or accessed for this purpose generally cannot alone be used to identify you. Technical storage or access is necessary to create user profiles, to send advertising or to track the user on a website or across multiple websites for similar marketing purposes. Accept cookies Reject Show settings Save settings Show settings. Manage consent. Scroll up.

Veterinary medicine cabinet

Buying MDMA pills Karlsruhe

Official websites use. Share sensitive information only on official, secure websites. PA coordinated the drafting and edited the text. AL-H reports grants and personal fees from Lundbeck, outside the submitted work. JR reports grants, personal and other fees from Lundbeck, outside the submitted work. All other authors report no conflicts of interest. No funds were used to prepare the paper. This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. In , illegal drug use was responsible for 1. No single European country has optimal governance structures for reducing the harm done by nicotine, illegal drugs and alcohol, and existing ones are poorly designed, fragmented, and sometimes cause harm. Reporting the main science and policy conclusions of a transdisciplinary five-year analysis of the place of addictions in Europe, researchers from 67 scientific institutions addressed these problems by reframing an understanding of addictions. A new paradigm needs to account for evolutionary evidence which suggests that humans are biologically predisposed to seek out drugs, and that, today, individuals face availability of high drug doses, consequently increasing the risk of harm. Tools of quantitative risk assessment that recognize drugs as toxins could be further deployed to assess regulatory approaches to reducing harm. Re-designed governance of drugs requires embedding policy within a comprehensive societal well-being frame that encompasses a range of domains of well-being, including quality of life, material living conditions and sustainability over time; such a frame adds arguments to the inappropriateness of policies that criminalize individuals for using drugs and that continue to categorize certain drugs as illegal. A health footprint, modelled on the carbon footprint, and using quantitative measures such as years of life lost due to death or disability, could serve as the accountability tool that apportions responsibility for who and what causes drug-related harm. Keywords: nicotine, illegal drugs, alcohol, evolutionary biology, governance, margins of exposure, well-being, health footprint. A consortium of 67 scientific institutions from 24 European countries and beyond, covering over thirty scientific disciplines ranging from anthropology to toxicology, responded to an invitation by the European Commission to study the place of addictions in contemporary European society. It reframed our understanding of addictions and formulated a blueprint for re-designing the governance of addictions. Although this paper does not cover process addictions e. The paper starts by discussing why we need to re-think addictions. It contrasts two powerful pieces of evidence: the harm done by drugs, versus the poorly structured existing governance approaches designed to manage such harm. The paper continues by considering three bases for re-thinking the addiction concept in ways that could lead to improved strategies across different jurisdictions: recognition that there is a biological predisposition for people to seek out and ingest drugs; that heavy use over time becomes a replacement concept and descriptor for the term substance use disorder; and that quantitative risk assessment can be used to standardize harm across different drugs, based on drug potency and exposure. The paper finishes by proposing two approaches that could strengthen addictions governance: embedding governance within a well-being frame, and adopting an accountability system—a health footprint that apportions responsibility for who and what causes drug-related harm. The need to re-think addictions is exemplified by the extent of harm caused by the drugs themselves, and by the fact that no single country, at least in Europe, has fully overcome poorly managed and fragmented governance structures. A standard way to document and describe the interference that drugs have on human biology and functioning is to use years of life lost to premature mortality YLL and disability adjusted life years DALYs. Source data available in Dataset 1 The data in Table 1 represents harm to the drug user. However, drug use also harms the health of others. For instance, operating machinery under the impact of illegal drugs can cause injury to others 8 , 9. The extent of harm to others caused by alcohol consumption is estimated to be proportionally even larger, mainly due to traffic accidents, violence, including homicide, and foetal alcohol spectrum disorders Data associated with the article are available under the terms of the Creative Commons Zero 'No rights reserved' data waiver CC0 1. Governance is defined as the processes and structures of public policy decision making and management that engage people across the boundaries of public agencies, levels of government, and public, private and civic spheres to carry out a public purpose that cannot be accomplished by any one sector alone The involvement of multiple stakeholders in governance is not without risk. An analysis of 28 European countries found that no single country had a comprehensive policy for all drugs including nicotine, illegal drugs and alcohol within a broad societal well-being approach. There are at least three reasons for ineffective and poorly integrated governance. Firstly, the same harm done by drugs is defined and understood in different ways in different countries and state systems 14 — Seen from a trans-national comparative perspective, there is a lack of a common understanding of appropriate policies, and responses are often constrained by approaches that are tied to assumptions that are not evidence-based 4. Ways of thinking about the harm done by drugs vary enormously, with considerable heterogeneity between different drugs, and between international, national and local levels of governance. Secondly, a multitude of commercial, political and public stakeholders are active in addictions governance on national and international levels. In any given society, stakeholders that have power, means and influence are likely to achieve an advantageous influential position. The concepts of addiction are also shaped by popular constructs promulgated by the mass media and customs in the general population. Stakeholder positions and perceptions of drug problems also vary over time and by area 4 , implying that sustainable approaches must be interwoven into societal and governance structures. Thirdly, corporate power 17 , through multiple channels of influence, can hinder evidence-based policy decisions 5. Corporate strategies often include attempts to influence civil society, science and the media, as part of a wider aim to manage and, if possible, capture institutions that set policy. Transparency is insufficient given that the multiplicity of channels with corporate power is poorly acknowledged and understood by policy makers. Therefore, the rules in place to ensure level playing fields for discussions and equitable decision-making across all factors are inadequate 6. The consensus reached under ALICE RAP was that there are at least three ways to reframe addictions that could lead to improved strategies across different jurisdictions. These include:. The idea that human exposure to drugs did not occur until late in human evolution—thus leaving our species inexperienced—is often posited as one of the reasons that these substances cause so much harm However, multidisciplinary scientific evidence suggests otherwise. Many substances consumed today are not evolutionary novelties 18 , Of the many defence mechanisms in existence, plants produce numerous chemicals, including tetrahydrocannabinol, cocaine, nicotine, and opiates, all of which are potent neurotoxins that deter consumption of plant tissue by animals From an evolutionary perspective, we thus find natural selection for compounds that discourage consumption of the plant via punishment of potential consumers. By contrast, there has been no natural selection for expression of psychoactive compounds which encourage consumption i. Many species of invertebrates and vertebrates engage in pharmacophagy, the deliberate consumption and sequestration of plant toxins, to dissuade parasites and predators. In a human context, present day examples of pharmacophagy may be seen with Congo basin hunter gatherers, amongst whom the quantity of cannabis 21 and nicotine 22 consumed is titrated against intestinal worm burden - the higher the intake, the lower the worm burden. In individuals treated with the anti-worm drug abendazole, the number of nicotine-containing cigarettes smoked is reduced Although parasite-host co-evolution is recognized as a potent selective force in nature, other, subtler evolutionary dynamics may affect human and animal interactions with plant-based drugs, including that they may buffer against nutritional and energetic constraints on signalling in the central nervous system Common plant toxins not only mimic mammalian neurotransmitters, they are also synthesized from the same nutritionally-constrained amino acid precursors, such as tyrosine and tryptophan. There is some evidence to support this hypothesis in animal research; for example, wood rats in cold environments reduce thermoregulatory costs by modulating body temperature with plant toxins consumed from the juniper plant In the case of ethanol, its presence within ripe fruit suggests low-level but chronic dietary exposure for all fruit-eating animals, with volatilized alcohols potentially serving in olfactory localization of nutritional resources i. Molecular evolutionary studies indicate that an oral digestive enzyme capable of rapidly metabolizing ethanol was modified in human ancestors near the time that they began extensively using the forest floor, about 10 million years ago 25 ; humans have retained the fast-acting enzyme to this day. By contrast, the same alcohol dehydrogenase in our more ancient and mostly tree-dwelling ancestors did not oxidize ethanol as efficiently. This evolutionary switch suggests that exposure to dietary sources of ethanol became more common as hominids adapted to bipedal life on the ground. Ripe fruits accumulating on the forest floor could provide substantially more ethanol cues and result in greater caloric gain relative to fruits ripening within the forest canopy, and our contemporary patterns of alcohol consumption and excessive use may accordingly reflect millions of years of natural dietary exposure This evolutionary evidence does not imply that humans also evolved to specifically consume nicotine, for example, or that nicotine use is beneficial in the modern world. What is novel in the modern world is the high degree of availability, and high concentration of psychoactive agents and routes of consumption that promote intoxication. What is different with alcohol in the modern world is novel availability through fermentative technology, enabling humans to consume it as a beverage, devoid of food bulk, with higher ethanol content, and artificially higher salience than that which characterizes fruit fermenting in the wild. The evolutionary evidence has two implications: firstly, policies that prohibit the use of drugs are likely to fail because people have a biological predisposition to seek out chemicals with varying nutritional and pharmacological properties; and secondly, in present-day society, drug delivery systems have been developed that are beyond what is reflected in the natural environment, particularly with respect to levels of potency, availability and taste, which could be argued as being the more central drivers of harm. Potency is largely determined by producer organisations operating in markets, which, from the perspective of overall societal well-being, are inadequately managed This is illustrated with alcohol. The associated chronic organ damage e. Unmanaged heavy drinking is associated with subsequent heavy drinking, often culminating in brain damage 32 , itself a consequence of heavy drinking 33 , 34 but also a driver of future behaviour. Alcohol consumption itself is close to log-normally distributed in drinking populations, skewed towards heavy drinking There is no natural cut-off point above which 'alcohol use disorder' definitively exists and below which it does not. Heavy drinking is a cause of the items on the checklist, including compulsion to drink more, which can also be a consequence of brain damage, itself caused by heavy drinking. For alcohol and other drugs as well , this approach does not imply that heavy use over time is the only cause of harm. There are other factors involved that that drive heavy alcohol use and harm 3 that are independent of, or in interaction with, molecular and cellular levels e. Framing the problem as one of heavy use over time provides insight into this debate. As with alcohol and high blood pressure 40 , chronic disease risk associated with plasma glucose levels has a continuous exponential relationship with sugar consumption The distribution of blood glucose levels is close to log-normally distributed in populations and skewed towards high consumption levels There is no natural cut-off point above which diabetes or any other disease manifestation linked to sugar definitively exists and below which it does not. Similar to the alcohol model where heavy use of alcohol over time leads to further heavy use of alcohol from the resulting brain damage, heavy use of sugar over time damages hippocampal function 43 , which leads to further heavy use of sugar over time A core way to document the interference of drugs in human biology and functioning is to use quantitative risk assessment QRA. QRA is a method applied in regulatory toxicology, for example, to evaluate water contaminants, and before safety approvals for food additives or pesticides. QRA has not been widely applied to drugs. Previous approaches for ranking harm have mostly been based on expert judgements 45 , 46 which have been criticized as being arbitrary and biased The advantage of QRA is that it provides a formal scientific method to rank the harm-potential of drugs, making optimum use of available data In the alcohol field, MOE has been applied to evaluate the liver cirrhosis risk of ethanol, which is the single most important chronic disease condition attributable to alcohol globally MOE results have replicated those behind existing guidelines for low-risk drinking In a detailed study of the components in alcoholic beverages, ethanol was confirmed as the compound with highest risk It can be concluded that the risk of alcoholic beverages can be evaluated by looking at the effects of ethanol alone. The situation is less clear for tobacco, for which some industry MOE studies find toxicants other than nicotine 54 , An MOE analysis of electronic cigarette liquids indicated that nicotine is the compound posing the highest risk The higher the MOE, the lower the level of risk, with low risk not implying safety. An MOE of means that the drug is being consumed at one hundredth of the benchmark dose; an MOE of 1 means that the drug is being consumed at this toxic dose. The MOE for drugs can be calculated taking into account a range of hazard outcomes in health and other well-being domains, as long as suitable dose-response data are available which is not the case for most drugs and many well-being indicators. Therefore, analyses to date are primarily restricted to lethal outcomes based on animal studies. Results for European adults are summarized in Figure 1. The low MOE for alcohol and thus high risk is due to the high levels of consumption by European adults. The MOE results are consistent with the consensus of expert rankings in which cannabis is ranked with lower risk and alcohol with higher risk than current policies assume 45 , The MOE is inherent to the drug itself; it does not account for the harms that arise from drug delivery systems, for example, smoked tobacco, or from secondary effects such as unclean syringes used for heroin intake. Of course, MOE, as presented here, focuses on the physical body of the adult user as the locus of harm. It does not take into account the sex and age of the user, or harm to individuals other than the user or at collective levels, which are a primary source of social differentiation between drugs. It also focuses on mortality, rather than intoxication in the moment. Differences between the intoxicating power of substances in the moment, and in the behavioural consequences of taking them, are primary reasons why, for example, societies have treated alcohol differently to tobacco. Nevertheless, we believe that MOE should be applied at the current stage even when the underlying toxicological data are incomplete, to provide a better alignment of prioritization of policy to the drugs associated with higher risks, which in this case are nicotine, cocaine, heroin and alcohol. We have described three harmonizing approaches to reframe our understanding of addictions: biological predisposition to seek out psychoactive substances; heavy use over time as a fruitful characterisation; and quantitative risk assessment. Here, we propose two underlying pillars for a re-design of the governance of drug controls: embedding drugs governance within a comprehensive model of societal well-being; and creating a health footprint which, modelled on the carbon footprint, promotes accountability by identifying who causes what harm to whom from drugs. We propose that societal well-being should be our overarching frame for a more integrated governance and monitoring of drug control policies. Societal well-being, as captured by OECD 57 , includes quality of life health, education and skills, social connections, civic engagement, and personal security , material conditions income, employment and housing and sustainability over time see Figure 2. Gross domestic product GDP is included as a separate domain, recognizing that, while economic well-being is an important component of societal well-being, GDP has significant limitations. GDP excludes, for example, non-market household activity such as parenting, and activities such as conservation of natural resources. GDP also includes activities which do not contribute to well-being, such as pollution and crime, termed regrettables that are depicted within GDP but outside well-being. The use of and harm done by drugs are affected by and affect all well-being dimensions Source: OECD. Well-being analyses have found that, whilst some illegal drug policies may reduce health harms, they often come with adverse side effects including criminalization, social stigma and social exclusion, all of which exacerbate health harms Humans are hard-wired to be social animals 60 , with social networks strongly influencing tobacco use 61 and alcohol intake Punitive drug policies bring about the opposite: social exclusion due to stigma and social isolation 63 — Engagement with illegal drugs conveys especially strong social meanings and can lead to stigma of marginalized heavy users, as opposed to the supposedly more responsible mainstream users This can lead to punitive societal responses. Meanwhile, exclusion from the mainstream may allow harms to continue unchecked. Changes in life expectancy in Mexico illustrate the negative consequences of criminalization After six decades of gains in life expectancy in Mexico, the trend stagnated after for both men and women, and for men was reversed after A well-being frame calls for whole-of-society approaches that progressively legalize illegal drugs to reduce violence and personal insecurity, while focusing on substances as drivers of harm 6 , It balances the complex factors impacting drug use and related harm through the continuous monitoring of policy effects in a proactive way, with regulations embedded in international coordination. It calls for whole-of-society approaches that avoid criminalization where possible and where costs of addressing the problem are equally distributed across society. Governance strategies manage nicotine, illegal drugs and alcohol as a whole to avoid overlaps, contradictions, gaps and inequalities 1. The concern should be focused on harms, both to the user and to others, including family and friends, communities and society as a whole. The structures to support the strategies should be coordinated and multi-sectoral, involving high-level coordination of health, social welfare, and justice agencies in the context of international treaties, and, importantly, equitable across the lifespan, between genders and cultural groups. To increase the pace of policy change, regional and local public policies can create policy communities and networks within a common international framework. An evolved governance system must include measures to avoid industry co-optation, through transparency, checks and balances. Private sector stakeholders should operate within established rules. The ongoing monitoring of outcomes within a well-being framework would promote accountability. Modelled on the carbon footprint, we propose a health footprint as the accountability tool. Footprints were developed in the ecological field as a measure of human demand on ecosystems 71 , including water footprints 72 and carbon footprints that apportion greenhouse gas emissions to certain activities, products and populations The central reason for estimating a carbon footprint is to help reduce the risk of climate change through enabling targeted and effective reductions in greenhouse gas emissions The health footprint can be considered a measure of the total amount of risk factor attributable disability adjusted life years DALYs 75 of a defined population, sector or action within a spatial e. Health footprints are a starting point. To be accountable, we ultimately need to understand what drives the health footprint Figure 3. Above the health footprint of Figure 3 are the structural drivers of harm that directly influence the size of the health footprint. Biological attributes and functions include, for example, the biological pre-disposition to seek out and use drugs. Genetic variants, for example, could be those that affect the function of alcohol dehydrogenase, influencing consumption levels and harm 8 , Changes in global population size and structure can increase absolute numbers of drug-related DALYs, even though rates per person can decrease over the same time 7. As sociodemographic status improves in lower income countries, so do drug-related DALYs 10 ; yet, for the same amount of drug use, people with lower incomes suffer more drug-related DALYs than people with higher incomes Above the structural drivers are the circumstantial drivers, those that can change. Related to drug potency and exposure, an MOE target for all drugs no greater than 10 has been argued 6. Policies could achieve such a result by either reducing drug exposure or by reducing the potency of the drug. Technological developments have led to electronic nicotine delivery systems widely known as e-cigarettes as widespread alternatives to smoked tobacco, with current best estimates showing e-cigarettes to be considerably less harmful to health than smoked cigarettes 78 — It may be that once e-cigarettes are heavily produced and marketed by the tobacco industry, that society will see cigarette-like levels of sustained heavy use of nicotine. Social influences and attitudes drive harm through stigma, social exclusion and social marginalization; these are often side-effects of drug policies, which can bring more harm than drug use itself 81 , Policies that reduce exposure to drugs are essentially those that limit availability by increasing the price and reducing physical availability 59 , 83 , The absence of such evidence-based policies is an important driver of harm. Individual choices and behaviour that drive harm from drug use are determined by the environment in which those choices and behaviours operate Banning commercial communications, increasing price and reducing availability are all incentives that impact individual behaviour. Research and development can be promoted to reduce the potency of existing drugs 87 and their drug delivery packages 27 , 56 , Unfortunately, there remain enormous gaps between the supply and demand of evidence-based prevention, advice and treatment programmes 88 — The harm driven by the gaps is due in large part to insufficient resources and insufficient implementation of effective evidence-based prevention and treatment programmes Similar to medicines agencies such as the European Medicines Agency that assess and approve drugs, prevention agencies could be created Compounding the gap between supply and demand is the fact that often, considerable marginalization and stigmatization happens in the path to treatment, and this is then further exacerbated by the treatment itself The use of pharmacotherapy as an adjunct may be further limited due to ideological stances, poorly implemented guidelines, lack of appropriate medication, and even a perceived lack of effect, if the drug is available The private sector is a core driver of harm, through commercial communications which include all actions undertaken by producers of drugs to persuade consumers to buy and consume more There are international models encouraging better control of commercial communications in the public health interest, the most notable being the Framework Convention on Tobacco Control In addition to commercial communications, the private sector drives harm through shaping drug policies, leading to more drug-related deaths 5. Governance structures thus need to have the capability and expertise to supervise industry movements that shape drug-related legislation and regulations, including regulating and restricting political lobbying. The health footprint is the accountability system for who and what causes drug-related harm. Jurisdictional entities can be ranked according to their overall health footprint, in order to identify the countries that contribute most to drug attributable ill-health and premature death, and where the most health gain could be achieved at country level. A range of sectors are involved in nicotine and alcohol related risk factors. These include producer and retail organizations such as large supermarket chains, and service provider companies such as advertising and marketing industries. There is considerable overlap between sectors, and estimates will need to determine appropriate boundaries for health footprint calculations. Companies could report their health footprints and choose to commit to reducing them by a specified amount over a five to ten-year time frame. Direct examples of producer action could include switching from higher to lower alcohol concentration products 27 , and switching from smoked tobacco cigarettes to e-cigarettes The points stated above underscore the need to redesign the governance of drugs; in Europe, and globally. Margins of exposure estimates for four drugs nicotine, cocaine, heroin and alcohol are exceedingly high and thus call for determined action. Drugs are responsible for a high proportion of years of life lost in the European Union; tobacco accounted for There are many side effects of existing policies, such as stigma, social exclusion, lack of personal security, civil unrest and homicide Under the auspices of ALICE RAP, a large, multidisciplinary team of addiction scientists put forward a range of arguments for moving progressively towards regulated legalization of certain illegal drugs, proposing a well-being frame that calls for whole-of-society approaches and continuously monitors and accounts for adverse side effects of drug policy. Humans have a biological pre-disposition to seek out a range of drugs, so prohibitionist policies are likely to run into difficulty - and they have. Legalization does not imply that drug governance is left to market forces alone - the experience of nicotine and alcohol demonstrates that this is not possible. Instead, drug governance requires comprehensive regulation, with adequate and transparent rules of the game for stakeholder involvement, and appropriate international regulatory frameworks. With a health footprint, it can be documented who causes what harm from nicotine, illegal drugs and alcohol in the public and private sectors. Public bodies and private companies should be required to publish their health footprints on an annual basis, and indicate their plans for reducing the health footprint. Without input from evolutionary theory, neurobiology will continue to maintain that human drug use is initiated and sustained by reward and reinforcement at both biological and behavioural levels, compounded by mistaken views that the human encounter with drugs is a relatively new evolutionary experience, and human vulnerability to drugs in moral, behavioural, and biological dimensions. Disease classification systems are based not only on measurement, but on qualification, and thus payment, for treatment. The concept heavy use over time does not prevent the use of qualification definitions for treatments. Threshold consumption levels determining treatment can be defined as levels above which advice and treatment have been shown to reduce the development or progression of end-organ damage. Extending margin of exposure analyses for a range of outcomes beyond mortality will overcome concern of one metric for drug policy - its strength is that it allows standard comparison across drugs and indicates options for changing both dose and exposure. Whilst measuring societal well-being as a whole has gained support, the implications for drug policy that favour regulated legalization will meet resistance from those who favour prohibition, particularly as prohibition is based more on a moral than an evidence-based standpoint, as has been the case with alcohol The footprint implies responsibility, which is often difficult for both public and private sectors to accept, in particular for producer companies whose vested interests might be challenged. What we propose in this paper are large adjustments to our understanding of addictions and to what needs to be done to effectively reduce the widespread harms done by drugs. We hope that what we have written might start a process for better drug policy for the good of the public. Dataset 1: Source data underlying the results presented in Table 1. DOI, The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. It will stimulate discussing on governance approaches that promote public health. Overall, this is a well-written article addressing the important topic of reframing the science and policy of nicotine, illegal drugs and alcohol. The main messages of the paper are clearly described and sufficiently accentuated. There is one important opinion that is included in the article that should be substantiated more extensively though. I would advise the authors to reconsider the terms used and to extend on the implications of the option they suggest. Second, and linked to this, the transition from the paragraph on the consequences of criminalization in Mexico and the plea for legalization on p. Next, there are some minor questions that arise at some paragraphs in the article we would like the authors to elaborate on. The authors propose to use DALYs as a measure for the health footprint. It is well known that the mis use of drugs result in an increased risk of a number of conditions somatic diseases, mental disorders, injuries. Relative risks together with prevalence data can serve as input to estimate substance-attributable fractions SAFs which can be used to quantify the economic burden of drug mis use. Do the authors imply that heavy use over time of sugar should be governed to the same extent as, e. Or do the authors plea for a differentiated substance policy between different types of substances? Does this mean that the focus should be on rewarding healthy lifestyle behavior? In addition, policy initiatives to reduce the use of sugar should be integrated together with other lifestyle-related interventions such as the promotion of more physical activity, healthy eating not restricted to only reducing the use of sugar. Please, add some comments on this. Could the authors add what the main reasons are why these data are missing and how this lack of data could be overcome? One might argue that taking one of these elements is suitable for prioritizing risk management as well? Could the authors thus more clearly argue why, they suggest to use MOE and not, e. What do the authors think about e. Could the authors briefly discuss each of the elements in this interesting figure? Could the authors please elaborate a bit more on the advantages added value and limitations of the conceptual model? We have read this submission. We believe that we have an appropriate level of expertise to confirm that it is of an acceptable scientific standard. The present manuscript by Anderson et al. The authors, and colleagues of associated publications, astutely highlight the need for a systematic lexicon for addiction science and policy. This lexicon is needed not only internationally but also intranationally at all levels of the private and public sector. Thus, the need to destigmatize addiction and recognize that it is a natural phenomenon requiring treatment, and not criminalization, in some individuals. This will require a 'reframing of addiction' in order to facilitate the treatment of addiction. While progress has been made in recognizing that addiction is a medical condition, that progress has not been matched by efforts to destigmatize addiction. Thus, addiction will continue to be criminalized with most funds targeting addiction policy being slated towards the criminal justice system rather than social and clinical medicine to treat the phenomenon. The authors put forth a hypothesis that the lack of consistent addiction policy not only internationally but also intranationally is the absence of a standardized measure of social, medical, economic, and civic damage resulting from addiction to different licit and illicit substances. Disability Adjusted Life Years DALYs is a recommended way to address the health impact disparity observed across different classes of substance with abuse potential. When this is done, as seen in Figure 1, it is clear that the licit substances ethanol and nicotine have a significantly greater deleterious 'health footprint' compared to most illicit drugs. Yet, global addiction policy is not consistent in recognizing, nor addressing, this disparity. Finally the authors recognize and remind the reader that addiction policy is influenced by social, political and market place suppositions that are not evidence-based. Moreover, with the nontransparency of lobbying activity by multiple, and diverse, stakeholders on policy makers will resist a 'reframing of addiction' in order for there to be consistent, equitable and humane policy both internationally and intranationally. As far as particular manuscript content goes, the authors discuss the relatively novel concept that plant neurotoxins, which many drugs of abuse mimic or contain, are evolutionarily conserved in the plant kingdom. Thus, these toxins dissuade animals from ingesting the plant. This point is receiving greater support through the recognition that immune signaling, centrally and peripherally, plays an important role in the neurobiology of addiction. I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard. This section collects any data citations, data availability statements, or supplementary materials included in this article. As a library, NLM provides access to scientific literature. Find articles by Peter Anderson. Find articles by Virginia Berridge. Find articles by Patricia Conrod. Find articles by Robert Dudley. Find articles by Matilda Hellman. Find articles by Dirk Lachenmeier. Find articles by Anne Lingford-Hughes. Find articles by David Miller. Find articles by Robin Room. Find articles by Laura Schmidt. Find articles by Roger Sullivan. Find articles by Tamyko Ysa. Find articles by Antoni Gual. Accepted Mar 16; Collection date Open in a new tab. Click here for additional data file. Find articles by Freya Vander Laenen. Find articles by Nick Verhaeghe. Competing interests: No competing interests were disclosed. Freya Vander Laenen : Referee. Nick Verhaeghe : Co-referee. PMC Copyright notice. Find articles by Richard L Bell. Richard L Bell : Referee. Associated Data. Similar articles. Add to Collections. Create a new collection. Add to an existing collection. Choose a collection Unable to load your collection due to an error Please try again. Add Cancel.

Buying MDMA pills Karlsruhe